What diseases does Adalimumab injection mainly treat?

Rheumatoid arthritis (RA) is one of the earliest and most commonly used indications for adalimumab. The disease is a chronic autoimmune disease characterized by symmetric inflammation of multiple joints, joint pain, swelling and even joint deformity. Adalimumab, as a tumor necrosis factor alpha (TNF-α) inhibitor, can effectively inhibit the inflammatory response and slow down the process of joint destruction. Often used in combination with methotrexate, it can significantly increase response rates and improve quality of life.

Adalimumab is widely used in inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. This type of disease mainly affects the gastrointestinal tract and often presents with symptoms such as abdominal pain, diarrhea, weight loss, and intestinal bleeding. Adalimumab controls intestinal inflammation and promotes intestinal mucosal healing by targeting blocking TNF-α. It is especially suitable for moderate to severe patients who have poor response to traditional immunosuppressants or glucocorticoids.

Psoriasis and psoriatic arthritis are also primary treatment indications for adalimumab. People with plaque psoriasis often experience itchy skin, red patches, and scales, while psoriatic arthritis also involves joint pain and limited mobility. Adalimumab can significantly reduce the area of u200bu200bskin lesions and the degree of inflammation, relieve joint symptoms, and improve the overall life function of patients. It is especially effective for those who are ineffective in traditional topical drugs or systemic treatments.

Adalimumab is also approved for the treatment of a variety of immune-related diseases including ankylosing spondylitis, uveitis, childhood idiopathic arthritis, and hidradenitis suppurativa. Ankylosing spondylitis patients are more common in young men and present with stiffness in the back and limited movement. Adalimumab can effectively relieve inflammation and pain. Adalimumab also delays visual impairment in patients with noninfectious intermediate, posterior, or panuveitis. In addition, it also shows good therapeutic prospects for children's autoimmune arthritis and chronic skin purulent lesions.

Reference materials:https://www.drugs.com/donanemab.html